BeyondSprings Lung Cancer Drug Shows 89 percent Disease Control Rate in Phase 2 Trial BYSI Stock News - StockTitan

BYSI Stock  USD 1.64  0.07  4.09%   
Under 54% of BeyondSpring's investor base is interested to short. The analysis of the overall investor sentiment regarding BeyondSpring suggests that many traders are impartial. BeyondSpring's investing sentiment shows overall attitude of investors towards BeyondSpring.
  
BeyondSprings Lung Cancer Drug Shows 89 percent Disease Control Rate in Phase 2 Trial BYSI Stock News StockTitan

Read at news.google.com
Google News at Macroaxis
  

BeyondSpring Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards BeyondSpring can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

BeyondSpring Fundamental Analysis

We analyze BeyondSpring's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeyondSpring using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeyondSpring based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Book

Price To Book Comparative Analysis

BeyondSpring is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

BeyondSpring Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeyondSpring stock to make a market-neutral strategy. Peer analysis of BeyondSpring could also be used in its relative valuation, which is a method of valuing BeyondSpring by comparing valuation metrics with similar companies.

Peers

BeyondSpring Related Equities

ARMPArmata Pharmaceuticals   4.29   
0%
13.0%
ADTXAditxt   2.94   
0%
9.0%
MCRBSeres Therapeutics   2.33   
0%
7.0%
SRZNSurrozen   1.44   
0%
4.0%
SLSSellas Life   1.16   
0%
3.0%
FBRXForte Biosciences   0.52   
0%
1.0%
KTTAPasithea Therapeutics   0.75   
2.0%
0%
INKTMink Therapeutics   1.59   
5.0%
0%
PLXProtalix Biotherapeutics   1.64   
5.0%
0%
ALVRAllovir   2.17   
6.0%
0%
MISTMilestone Pharmaceuticals   3.23   
10.0%
0%
ONCYOncolytics Biotech   3.57   
11.0%
0%
SCPHScpharmaceuticals   3.63   
11.0%
0%
RVPHReviva Pharmaceuticals   5.78   
18.0%
0%
EYPTEyepoint Pharmaceuticals   6.05   
19.0%
0%
CADLCandel Therapeutics   31.12   
100.0%
0%

Complementary Tools for BeyondSpring Stock analysis

When running BeyondSpring's price analysis, check to measure BeyondSpring's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeyondSpring is operating at the current time. Most of BeyondSpring's value examination focuses on studying past and present price action to predict the probability of BeyondSpring's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeyondSpring's price. Additionally, you may evaluate how the addition of BeyondSpring to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Commodity Directory
Find actively traded commodities issued by global exchanges